Compare ResMed Inc. (RMD) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tilray Brands Inc — how do they compare? ResMed Inc. trades at $194.16 (market cap $28.81B), while Tilray Brands Inc trades at $4.25 (market cap $524.07M). The key difference: ResMed Inc. is far larger — about 55× Tilray Brands Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| RMD | TLRY | |
|---|---|---|
Market Cap | $28.81B | $524.07M |
Sector | Health | Health |
52-Week High | $293.73 | $21.00 |
52-Week Low | $182.82 | $4.23 |
Enterprise Value | $27.99B | $621.22M |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
